ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.49 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.46M shares, a 2315.13% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 29.30K shares, a 95.90% decline year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 400.00 shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 774.80K shares, a 56.36% decline from fiscal 2024.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.78M shares, a 206.66% increase from fiscal 2023.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 578.91K shares, a 72.01% decline from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.07M shares, a 41.55% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.46M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 1.49M shares 10-Q · filed 2026-08-04 | 1.49M shares derived: sum of 3 quarters · filed 2026-08-04 | 1.49M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 29.30K shares 10-Q · filed 2026-05-05 | 29.30K shares derived: sum of 2 quarters · filed 2026-05-05 | 29.70K shares derived: sum of 3 quarters · filed 2026-05-05 | 90.00K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 400.00 shares derived: sum of 2 quarters · filed 2026-03-12 | 60.70K shares derived: sum of 3 quarters · filed 2026-03-12 | 774.80K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 400.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 60.70K shares derived: sum of 2 quarters · filed 2025-11-06 | 774.80K shares 10-Q · filed 2025-11-06 | 2.55M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 60.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 774.40K shares 10-Q · filed 2025-08-12 | 2.55M shares derived: sum of 3 quarters · filed 2025-08-12 | 2.55M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 714.10K shares 10-Q · filed 2025-05-06 | 2.49M shares derived: sum of 2 quarters · filed 2025-05-06 | 2.49M shares derived: sum of 3 quarters · filed 2025-05-06 | 2.49M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 1.78M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 1.78M shares derived: sum of 2 quarters · filed 2025-03-10 | 1.78M shares derived: sum of 3 quarters · filed 2025-03-10 | 1.78M shares 10-K · filed 2025-03-10 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-07 | 0.00 shares 10-Q · filed 2024-11-07 | 30.00K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 0.00 shares 10-Q · filed 2024-08-13 | 30.00K shares derived: sum of 3 quarters · filed 2024-08-13 | 196.00K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-07 | 30.00K shares derived: sum of 2 quarters · filed 2024-05-07 | 196.00K shares derived: sum of 3 quarters · filed 2024-05-07 | 443.31K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 30.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 196.00K shares derived: sum of 2 quarters · filed 2024-03-28 | 443.31K shares derived: sum of 3 quarters · filed 2024-03-28 | 578.91K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 166.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 413.31K shares derived: sum of 2 quarters · filed 2023-11-13 | 548.91K shares 10-Q · filed 2023-11-13 | 2.06M shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 247.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 382.92K shares 10-Q · filed 2023-08-10 | 1.90M shares derived: sum of 3 quarters · filed 2023-08-10 | 2.04M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 135.60K shares 10-Q · filed 2023-05-11 | 1.65M shares derived: sum of 2 quarters · filed 2023-05-11 | 1.80M shares derived: sum of 3 quarters · filed 2023-05-11 | 1.97M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 1.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 1.66M shares derived: sum of 2 quarters · filed 2023-03-27 | 1.83M shares derived: sum of 3 quarters · filed 2023-03-27 | 2.07M shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 149.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 321.98K shares derived: sum of 2 quarters · filed 2022-11-08 | 555.58K shares 10-Q · filed 2022-11-08 | 1.61M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 172.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 405.98K shares 10-Q · filed 2022-08-09 | 1.46M shares derived: sum of 3 quarters · filed 2022-08-09 | 1.59M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 233.60K shares 10-Q · filed 2022-05-10 | 1.28M shares derived: sum of 2 quarters · filed 2022-05-10 | 1.41M shares derived: sum of 3 quarters · filed 2022-05-10 | 1.50M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 1.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | 1.18M shares derived: sum of 2 quarters · filed 2022-03-23 | 1.26M shares derived: sum of 3 quarters · filed 2022-03-23 | 3.54M shares 10-K · filed 2022-03-23 |
| 2021-09-30 | 130.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 214.00K shares derived: sum of 2 quarters · filed 2021-11-12 | 2.49M shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 84.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 2.36M shares 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | 2.27M shares 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |